X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (116) 116
index medicus (115) 115
oncology (114) 114
female (99) 99
middle aged (94) 94
male (83) 83
adult (80) 80
aged (76) 76
chemotherapy (65) 65
cancer (55) 55
prognosis (44) 44
aged, 80 and over (43) 43
original (39) 39
original article (36) 36
retrospective studies (35) 35
survival (35) 35
treatment outcome (33) 33
disease-free survival (30) 30
care and treatment (28) 28
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
gefitinib (27) 27
lung neoplasms - drug therapy (27) 27
mutation (26) 26
neoplasm staging (26) 26
adenocarcinoma (25) 25
metastasis (24) 24
lung cancer (23) 23
tumors (23) 23
의약학 (23) 23
analysis (22) 22
carcinoma, non-small-cell lung - drug therapy (22) 22
young adult (22) 22
antineoplastic agents - therapeutic use (21) 21
lung neoplasms - genetics (21) 21
patients (20) 20
breast cancer (19) 19
research (19) 19
therapy (19) 19
carcinoma (18) 18
kaplan-meier estimate (18) 18
receptor, epidermal growth factor - genetics (17) 17
erlotinib (16) 16
lung neoplasms - pathology (16) 16
medicine & public health (16) 16
neoadjuvant therapy (16) 16
surgery (16) 16
breast neoplasms - drug therapy (15) 15
carcinoma, non-small-cell lung - genetics (15) 15
immunohistochemistry (15) 15
immunotherapy (15) 15
medical colleges (15) 15
proportional hazards models (15) 15
respiratory system (15) 15
docetaxel (14) 14
egfr (14) 14
expression (14) 14
metastases (14) 14
pembrolizumab (14) 14
survival analysis (14) 14
cancer research (13) 13
cell lung-cancer (13) 13
medical prognosis (13) 13
multivariate analysis (13) 13
survival rate (13) 13
trial (13) 13
abridged index medicus (12) 12
adolescent (12) 12
breast neoplasms - pathology (12) 12
cancer patients (12) 12
epidermal growth factor (12) 12
epidermal growth factor receptor (12) 12
genetic aspects (12) 12
medicine, general & internal (12) 12
cisplatin (11) 11
doxorubicin (11) 11
follow-up studies (11) 11
hematology, oncology and palliative medicine (11) 11
lung cancer, non-small cell (11) 11
mutations (11) 11
neoadjuvant chemotherapy (11) 11
protein kinase inhibitors - therapeutic use (11) 11
resistance (11) 11
usage (11) 11
adenocarcinoma - genetics (10) 10
growth-factor receptor (10) 10
health aspects (10) 10
hematology (10) 10
induction chemotherapy (10) 10
internal medicine (10) 10
medical research (10) 10
neoplasm metastasis (10) 10
pulmonary/respiratory (10) 10
receptor, epidermal growth factor - antagonists & inhibitors (10) 10
toxicity (10) 10
adenocarcinoma - drug therapy (9) 9
adjuvant treatment (9) 9
anaplastic lymphoma kinase (9) 9
apoptosis (9) 9
carcinoma, squamous cell - mortality (9) 9
carcinoma, squamous cell - pathology (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2018, 15
Reference
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 2018, Volume 37, Issue 3, pp. 579 - 583
Despite the lack of safety and efficacy data regarding immune checkpoint inhibitors (ICIs) for renal dysfunction, they have been approved to treat even in the... 
Immune checkpoint inhibitor | End-stage renal disease | Dialysis | Physiological aspects | Immune response | Research | Chronic kidney failure | Drug therapy | Pharmacokinetics | Renal function | Effectiveness | Medicare | Hemodialysis | Toxicity | Pharmacology | Patients | Literature reviews | Pneumonitis | Inhibitors | Immune checkpoint | Kidney diseases | Safety
Journal Article
British Journal of Cancer, ISSN 0007-0920, 07/2018, Volume 119, Issue 2, pp. 153 - 159
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 194 - 206
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 7, pp. 1273 - 1273
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 3/2018, Volume 67, Issue 3, pp. 459 - 470
We investigated inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) that may predict the response to anti-PD-1 (programmed cell death protein... 
Prognostic value | Immunology | Prognosis | Medicine & Public Health | Neutrophil-to-lymphocyte ratio | Anti-PD-1 antibody | Immunotherapy | Oncology | Cancer Research | SURVIVAL | MANAGEMENT | IMMUNOLOGY | CHEMOTHERAPY | METASTATIC MELANOMA | PREDICTS PROGNOSIS | ONCOLOGY | PRETREATMENT NEUTROPHIL | EXPERIENCE | NIVOLUMAB | EXPRESSION | IPILIMUMAB | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Follow-Up Studies | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adenocarcinoma - metabolism | Aged, 80 and over | Adult | Female | Retrospective Studies | Neutrophils - pathology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Non-Small-Cell Lung - metabolism | Survival Rate | Adenocarcinoma - drug therapy | Lymphocytes - pathology | Carcinoma, Squamous Cell - drug therapy | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Viral antibodies | Complications and side effects | Liver cancer | Medical colleges | Care and treatment | Lymphocytes | Cell death | Analysis | Antibodies | Metastasis | Lung cancer, Non-small cell | Brain | PD-1 protein | Liver | Lung cancer | Neutrophils | Non-small cell lung carcinoma | Inflammation | Multivariate analysis | Survival | Patients | Metastases | Confidence intervals | Medical prognosis | Bioindicators | Movement disorders | Cancer | Apoptosis
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 7, pp. 1273 - 1273
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2016, Volume 34, Issue 32, pp. 3838 - 3845
Journal Article